Angiotensin-Converting Enzyme Inhibitor Therapy Effects in Patients With Heart Failure With Preserved and Mid-Range Ejection Fraction

Safonova, Julia; Kozhevnikova, Maria; Danilogorskaya, Yu A; Zheleznykh, E A; Zektser, Vita; Ilgisonis, I S; Попова, Л.В.; Khabarova, N V; Privalova, E V; Belenkov, Yu. N.

doi:10.14740/cr1322

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perindopril is the only ACEI that has been shown to improve endothelial function. Notably, Safonova et al demonstrated that after 12-month therapy with perindopril, ET-1 level decreased significantly in both HFpEF and HFmrEF patients [ 100 ]. In addition, other studies have shown that captopril and lisinopril caused a significant reduction in ET-1 production [ 101 , 102 ].…”

Section: Endothelin-1: a Promising Biomarker In Ahfmentioning

confidence: 99%

Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?

Dmour,

Costache,

Dmour

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Acute heart failure (AHF) is a life-threatening condition with high morbidity and mortality. Even though this pathology has been extensively researched, there are still challenges in establishing an accurate and early diagnosis, determining the long- and short-term prognosis and choosing a targeted therapeutic strategy. The use of reliable biomarkers to support clinical judgment has been shown to improve the management of AHF patients. Despite a large pool of interesting candidate biomarkers, endothelin-1 (ET-1) appears to be involved in multiple aspects of AHF pathogenesis that include neurohormonal activation, cardiac remodeling, endothelial dysfunction, inflammation, atherosclerosis and alteration of the renal function. Since its discovery, numerous studies have shown that the level of ET-1 is associated with the severity of symptoms and cardiac dysfunction in this pathology. The purpose of this paper is to review the existing information on ET-1 and answer the question of whether this neurohormone could be a promising biomarker in AHF.

show abstract

Section: Endothelin-1: a Promising Biomarker In Ahfmentioning

confidence: 99%

Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?

Dmour,

Costache,

Dmour

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

Endothelin-1, Extracellular Volume Overload, and Hemodynamics in Hemodialysis Patients

Horvit,

Jeon-Slaughter,

Sian

et al. 2024

American Journal of Hypertension

View full text Add to dashboard Cite

Introduction Extracellular volume (ECV) overload and endothelial cell dysfunction (ECD) are independent risk factors for mortality in hemodialysis patients. Endothelin-1 (ET-1), an endothelium-derived vasoconstrictive peptide, is associated with poor outcomes in hemodialysis patients and heart failure patients without kidney disease. We hypothesized there would be associations between ET-1 and ECV overload assessed with bioimpedance spectroscopy (BIS) in hypertensive hemodialysis patients. Methods We obtained pre-HD plasma ET-1, ECV/weight (using multi-frequency BIS), pre-HD hemodynamic measurements, and ambulatory blood pressure (BP) in a cohort of HD patients. Following appropriate transformations, we conducted correlation and linear regression analyses to identify associations between ET-1 and ECV overload. We further explored associations between ET-1 and total peripheral resistance index (TPRI), cardiac index (CI), and ambulatory BP. Results Among 66 patients, median ET-1 was 1.93 (1.49-2.56) pg/mL. Median pre-HD ECV/weight, median TPRI, mean CI, and mean systolic ambulatory BP were 0.25 (0.22-0.30) L/kg, 3161 (2711-3642) dynes*sec/cm-5/m2, 2.92 (0.6) L/min/m2, and 143 (14) mmHg, respectively. After reciprocal transformation, ET-1 correlated with reciprocal-transformed ECV/weight (r=0.3, p=.01), log-transformed TPRI (r=-0.3, p=.006), CI (r=0.3, p=.009) and ambulatory BP (r=-0.3, p=.02). Controlling for demographic variables, these associations persisted in linear regression analysis (β=0.15, p=.002; β=-0.8, p=.002; β=0.2, p=.002; β=-19, p=.03). Conclusions In hypertensive HD patients, ECV overload is associated with ET-1. ET-1 is associated with higher TPRI and lower CI before dialysis and higher ambulatory BP. Further research is necessary to determine if ECV reduction lowers ET-1 or if pharmacologic ET-1 antagonism can improve outcomes in HD patients with refractory ECV overload.

show abstract

Evaluation of Plasma E-Selectin Concentration as a Risk Marker for Atherosclerotic Vascular Damage in Patients with Early CAD

Rac,

Krzystolik

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Background: Inflammation markers in the blood may indicate a higher risk of unstable atherosclerosis. Selectins, a group of transmembrane glycoproteins, contribute to inflammation by helping certain blood cells bind to the endothelium. Methods: The study included 100 patients with stable early-onset coronary artery disease (CAD), 75 men (aged 50–54) and 25 women (aged 55–64). Tests performed included biochemical analysis, ultrasound, and Doppler imaging of arteries and peripheral vessels. A biochemical control group of 50 cases without CAD (74% men, average age 48 ± 3.20 years) was also studied. Results: Higher triglyceride levels were strongly linked to elevated plasma E-selectin levels. However, no significant relationship was found between plasma E-selectin levels and biochemical, clinical, radiographic, or echographic measures. Conclusion: Plasma E-selectin levels are not a reliable marker for detecting atherosclerotic plaques or related problems in individuals with stable, well-managed CAD. While E-selectin levels can be measured in clinical labs using immunoassays, they cannot replace standard cardiological and vascular imaging tests for diagnosing cardiac or vascular conditions.

show abstract

Angiotensin-Converting Enzyme Inhibitor Therapy Effects in Patients With Heart Failure With Preserved and Mid-Range Ejection Fraction

Cited by 3 publications

References 14 publications

Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?

Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?

Endothelin-1, Extracellular Volume Overload, and Hemodynamics in Hemodialysis Patients

Evaluation of Plasma E-Selectin Concentration as a Risk Marker for Atherosclerotic Vascular Damage in Patients with Early CAD

Contact Info

Product

Resources

About